Contributing to Society Through Pharmaceutical Development for Rare and Intractable Diseases
First written in FY2016. 18 of 23 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「The Group has adopted “creating value through biotechnology—seeking to provide care that embraces children, families and society” as its corporate philosophy and “helping children and enabling children to help others” as its management vision.」
The company is reaffirming its corporate philosophy and its management policy of providing care that embraces children, families and society, as well as treatments that support children. - FY2024-Q3RestatedAnnual report
「We have adopted “creating value through biotechnology—seeking to provide care that embraces children, families and society” as our management philosophy. Making maximum use of the biotechnology expertise and knowledge gained through our research, development and business activities since our founding, we aim to provide comprehensive care for patients, their families and caregivers, primarily through research, development and the provision of not only new drugs but also new forms of healthcare in the fields of rare diseases, intractable diseases and pediatric diseases.」
The company is reaffirming its corporate philosophy of providing comprehensive care for patients, families and caregivers with a focus on rare diseases, intractable diseases and pediatric diseases, through new forms of healthcare as well as new drugs. - FY2023ReframedAnnual report
「Under its corporate philosophy of “creating value through biotechnology—seeking to provide care that embraces children, families and society,” we continue our activities with the aim of using to the fullest extent our expertise in drug development and track record of bringing products to market, cultivated since our founding, to provide new treatments and therapies promptly to patients suffering from disease and contribute to realizing a society in which people of all ages, including children and the adults who support them, can live happy and fulfilling lives.」
The company has set out its longstanding policy of contributing to society and providing comprehensive care within a sustainability framework based on its corporate philosophy and the SDGs and ESG, particularly its contribution to the “S” (social) dimension. - FY2023-Q3RestatedAnnual report
「We have established as our goal “creating value through biotechnology—seeking to provide care that embraces children, families and society.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company is reaffirming its policy of targeting rare diseases, intractable diseases and pediatric diseases, and seeking to provide comprehensive care that embraces children, families and society, as well as developing and providing new forms of healthcare. - FY2023-Q2RestatedAnnual report
「We have established as our goal “creating value through biotechnology—seeking to provide care that embraces children, families and society.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company is reaffirming its policy of targeting rare diseases, intractable diseases and pediatric diseases, and seeking to provide comprehensive care that embraces children, families and society, as well as developing and providing new forms of healthcare. - FY2023-Q1RestatedAnnual report
「We have established as our goal “creating value through biotechnology—seeking to provide care that embraces children, families and society.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company is reaffirming its policy of targeting rare diseases, intractable diseases and pediatric diseases, and seeking to provide comprehensive care that embraces children, families and society, as well as developing and providing new forms of healthcare. - FY2022RaisedAnnual report
「We have established as our goal “creating value through biotechnology—seeking to provide care that embraces children, families and society.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. With “helping children and enabling children to help others” as keywords for our drug discovery activities, we are working to develop and provide not only new drugs but also new forms of healthcare for people of all generations, including patients suffering from various diseases, their families and caregivers, by making use of young-source stem cells such as SHED, as well as enhancing medical care for pediatric diseases.」
In addition to its traditional efforts in rare diseases, intractable diseases and pediatric diseases, the company has explicitly adopted “care that embraces children, families and society” and expanded its scope to healthcare for all generations through the use of young-source stem cells such as SHED. - FY2022-Q3RestatedAnnual report
「To realize “creating value through biotechnology,” we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed, making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date. To accelerate the development and provision of not only new drugs but also new forms of healthcare, aimed at delivering comprehensive care to patients suffering from these diseases, their families and caregivers, we began anew as Kidswell Bio Corporation on 1 July 2021. We are strengthening our activities with renewed determination and as one company in order to reliably achieve the specific strategies and performance targets for each business set out in the five-year medium-term management plan announced on 15 February 2021.」
Under “creating value through biotechnology,” the company is reaffirming its focus on rare diseases, intractable diseases and pediatric diseases, its provision of comprehensive care, its development and provision of new forms of healthcare, and its strengthened efforts to achieve the five-year medium-term management plan. - FY2022-Q2RestatedAnnual report
「To realize “creating value through biotechnology,” we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed, making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date. To accelerate the development and provision of not only new drugs but also new forms of healthcare, aimed at delivering comprehensive care to patients suffering from these diseases, their families and caregivers, we began anew as Kidswell Bio Corporation on 1 July 2021. We are strengthening our activities with renewed determination and as one company in order to reliably achieve the specific strategies and performance targets for each business set out in the five-year medium-term management plan announced on 15 February 2021.」
The company is reaffirming its direction of “creating value through biotechnology,” focusing on rare diseases, intractable diseases and pediatric diseases, providing comprehensive care and developing and providing new forms of healthcare, together with strengthened efforts to achieve the five-year medium-term management plan. - FY2022-Q1ReframedAnnual report
「To realize “creating value through biotechnology,” we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed, making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date. To accelerate the development and provision of not only new drugs but also new forms of healthcare, aimed at delivering comprehensive care to patients suffering from these diseases, their families and caregivers, we began anew as Kidswell Bio Corporation on 1 July 2021. We are strengthening our activities with renewed determination and as one company in order to reliably achieve the specific strategies and performance targets for each business set out in the five-year medium-term management plan announced on 15 February 2021.」
The company has maintained the previous direction of GTS3.0 while changing the expression to “creating value through biotechnology” and restarting as Kidswell Bio Corporation. It continues to pursue pediatric diseases, comprehensive care, the development and provision of new forms of healthcare, and achievement of the five-year medium-term management plan. - FY2021-Q3RestatedAnnual report
「We have established GTS3.0, a new business stage, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
Under GTS3.0, the company is reaffirming its direction of focusing on pediatric diseases in addition to rare and intractable diseases, and developing and providing comprehensive care and new forms of healthcare for patients, families and caregivers. - FY2021-Q1RestatedAnnual report
「We have established GTS3.0, a new business stage, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
Under GTS3.0, the company is reaffirming its direction of focusing on pediatric diseases in addition to rare and intractable diseases, and developing and providing comprehensive care and new forms of healthcare for patients, families and caregivers. - FY2020RestatedAnnual report
「As a university-launched venture, we operate in accordance with the spirit of serving the public. In addition to contributing to society through the pursuit of corporate profits, we are engaged in the development of drugs to treat rare and intractable diseases, working to eliminate disparities in access to healthcare and make a detailed contribution to improving people's quality of life, thereby providing a fulfilling and secure social environment. We devote ourselves to research and development every day.」
The company is reaffirming its management philosophy of contributing to society and improving quality of life through drug development for rare and intractable diseases. - FY2020-Q3RestatedAnnual report
「We have established GTS3.0, a new business stage, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
Under GTS3.0, the company is reaffirming its direction of focusing on pediatric diseases in addition to rare and intractable diseases, and developing and providing comprehensive care and new forms of healthcare for patients, families and caregivers. - FY2020-Q1RestatedAnnual report
「We have established GTS3.0, a new business stage, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the biotechnology expertise and knowledge acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company is reaffirming its direction under GTS3.0: focusing on pediatric diseases in addition to rare and intractable diseases, providing comprehensive care for patients, families and caregivers, and developing and providing new forms of healthcare beyond new drugs. - FY2019RestatedAnnual report
「As a university-launched venture, we operate in accordance with the spirit of serving the public. In addition to contributing to society through the pursuit of corporate profits, we are engaged in the development of drugs to treat rare and intractable diseases, working to eliminate disparities in access to healthcare and make a detailed contribution to improving people's quality of life, thereby providing a fulfilling and secure social environment. We devote ourselves to research and development every day.」
The company is reaffirming its management philosophy of developing drugs for rare and intractable diseases, eliminating disparities in access to healthcare and improving quality of life. - FY2019-Q3RaisedAnnual report
「Having progressed through the GTS1.0 and GTS2.0 stages, from the current fiscal year we have established GTS3.0, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the expertise and technologies acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company has identified pediatric diseases as a key target in addition to its traditional focus on rare and intractable diseases, and has set out the GTS3.0 goal of developing and providing comprehensive care and new forms of healthcare. - FY2019-Q1RestatedAnnual report
「Through these efforts, we seek both to deliver higher-quality, lower-cost biopharmaceuticals to more patients accurately and promptly and to achieve further growth for the company.」
The company is reaffirming its commitment to contributing to society by delivering high-quality, low-cost biopharmaceuticals to more patients. - FY2018RestatedAnnual report
「As a university-launched venture, we operate in accordance with the spirit of serving the public. In addition to contributing to society through the pursuit of corporate profits, we are engaged in the development of drugs to treat rare and intractable diseases, working to eliminate disparities in access to healthcare and make a detailed contribution to improving people's quality of life, thereby providing a fulfilling and secure social environment. We devote ourselves to research and development every day.」
The company is reaffirming in its annual report its management philosophy of developing drugs for rare and intractable diseases, eliminating disparities in access to healthcare and improving quality of life. - FY2018-Q2RestatedAnnual report
「Through these efforts, we seek both to deliver higher-quality, lower-cost biopharmaceuticals to more patients accurately and promptly and to achieve further growth for the company.」
The company is reaffirming its commitment to contributing to society by delivering high-quality, low-cost biopharmaceuticals to more patients. - FY2017RestatedAnnual report
「As a university-launched venture, we operate in accordance with the spirit of serving the public. In addition to contributing to society through the pursuit of corporate profits, we are engaged in the development of drugs to treat rare and intractable diseases, working to eliminate disparities in access to healthcare and make a detailed contribution to improving people's quality of life, thereby providing a fulfilling and secure social environment. We devote ourselves to research and development every day.」
The company is reaffirming its management philosophy of eliminating disparities in access to healthcare and improving quality of life through drug development for rare and intractable diseases. - FY2017-Q3RestatedAnnual report
「To achieve further growth for the company and deliver higher-quality, lower-cost biopharmaceuticals to more patients accurately and promptly」
The company is reaffirming its commitment to contributing to society by delivering high-quality, low-cost biopharmaceuticals to patients. - FY2016First statedAnnual report
「As befits the public mission of a university-launched venture, we seek not only to generate profits but also to improve people's quality of life and contribute to society through the development of drugs for rare and intractable diseases.」
The company has adopted as its management philosophy not only the pursuit of profit, but also the treatment of rare and intractable diseases and the improvement of patients' quality of life.